Headquartered in Buffalo, New York, 22nd Century Group is a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research.

XXII investing in expanded marketing initiatives to drive VLN® brand awareness and growthMOCKSVILLE, N.C., July 16, 2026 (GLOBE NEWSWIRE) -- ...

Reduced Cost Structure Expected to Save more than $1Million Annually in 2024, Aligns Board with Corporate-Wide Lean Operating Commitment "We continue to build on our progress over the past two months ...

22nd Century announces readiness to support the FDA's proposed standard to reduce nicotine content in cigarettes. The possible regulation passed review by the U.S. Office of Management and Budget on ...

Year to Date Total Debt Reduction of approximately $3.8 Million 22nd Century will report its complete first quarter results on May 13, 2025, with a conference call the same day. About 22nd Century ...

XXII on Monday announced it had signed a binding agreement with its senior secured lender to eliminate its senior secured debt through potential debt-for-equity exchanges. Additionally, it has ...

Lawrence D. Firestone, President, CEO & Chairman, emphasized the company's leadership in tobacco harm reduction, highlighting the proprietary low nicotine tobacco strains forming the basis of their 95 ...

) has been revised to $137.70 / share. This is an increase of 1,400.00% from the prior estimate of $9.18 dated January 11, 2026. The price target is an average of many targets provided by analysts.

The U.S. Food and Drug Administration (FDA) has accepted for scientific review two Modified Risk Tobacco Product (MRTP) renewal applications from 22nd Century Group, a tobacco harm reduction company ...

22nd Century Group (XXII) has completed product prototyping and the initial analytical evaluations necessary for advancing the regulatory process for its reduced-nicotine cigarette. The company ...